ProCE Banner Activity

EQoL-MDS: Eltrombopag in Low, Int-1 IPSS Risk MDS

Slideset Download
Conference Coverage
Phase II data suggest that eltrombopag is effective with a toxicity profile similar to placebo.

Released: December 07, 2015

Expiration: December 05, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen